MedicalSentry

Health Research Company

PAXIL

generic name is paroxetine hydrochloride

Why is this drug subscribed ?

Paroxetine tablets, suspension (liquid), and extended-release (long-acting) tablets are used to treat depression, panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks), and social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life). Paroxetine tablets and suspension are also used to treat obsessive-compulsive disorder (bothersome thoughts that won't go away and the need to perform certain actions over and over), generalized anxiety disorder (GAD; excessive worrying that is difficult to control), and posttraumatic stress disorder (disturbing psychological symptoms that develop after a frightening experience). Paroxetine extended-release tablets are also used to treat premenstrual dysphoric disorder (PMDD, physical and psychological symptoms that occur before the onset of the menstrual period each month). Paroxetine is in a class of medications called selective serotonin-reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance.

Active Substance: PAROXETINE HYDROCHLORIDE

PAXIL Available Drugs :

PAXIL ndc# 0029-3211

by GlaxoSmithKline LLC

ORAL TABLET, FILM COATED with active strength of 20 mg/1

started marketing at 14/01/1993 .

PAXIL ndc# 0029-3210

by GlaxoSmithKline LLC

ORAL TABLET, FILM COATED with active strength of 10 mg/1

started marketing at 27/03/1996 .

PAXIL ndc# 0029-3213

by GlaxoSmithKline LLC

ORAL TABLET, FILM COATED with active strength of 40 mg/1

started marketing at 27/03/1996 .

PAXIL ndc# 0029-3212

by GlaxoSmithKline LLC

ORAL TABLET, FILM COATED with active strength of 30 mg/1

started marketing at 05/01/1993 .

PAXIL ndc# 0029-3215

by GlaxoSmithKline LLC

ORAL SUSPENSION with active strength of 10 mg/5mL

started marketing at 06/02/1998 .

PAXIL ndc# 21695-160

by Rebel Distributors Corp

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 25 mg/1

started marketing at 09/04/2002 .

PAXIL ndc# 21695-159

by Rebel Distributors Corp

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 12.5 mg/1

started marketing at 09/04/2002 .

PAXIL ndc# 0029-4607

by GlaxoSmithKline LLC

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 25 mg/1

started marketing at 17/06/2010 .

PAXIL ndc# 16590-514

by STAT RX USA LLC

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 12.5 mg/1

started marketing at 09/04/2002 .

PAXIL ndc# 54868-2976

by Physicians Total Care, Inc.

ORAL TABLET, FILM COATED with active strength of 20 mg/1

started marketing at 18/09/2006 .

PAXIL ndc# 60505-3670

by Apotex Corp

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 37.5 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3663

by Apotex Corp

ORAL TABLET, FILM COATED with active strength of 10 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3664

by Apotex Corp

ORAL TABLET, FILM COATED with active strength of 20 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3665

by Apotex Corp

ORAL TABLET, FILM COATED with active strength of 30 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3666

by Apotex Corp

ORAL TABLET, FILM COATED with active strength of 40 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3669

by Apotex Corp

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 25 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 60505-3668

by Apotex Corp

ORAL TABLET, FILM COATED, EXTENDED RELEASE with active strength of 12.5 mg/1

started marketing at 01/01/2011 .

PAXIL ndc# 54868-3526

by Physicians Total Care, Inc.

ORAL TABLET, FILM COATED with active strength of 30 mg/1

started marketing at 10/07/1996 .

PAXIL ndc# 60505-0402

by Apotex Corp

ORAL SUSPENSION with active strength of 10 mg/5mL

started marketing at 01/01/2011 .

PAXIL Search Trends:

News :

Social Buzz

comments powered by Disqus